Assess whether the primary endpoint will survive FDA scrutiny (374ef4)

SITUATION 505(b)(2) literature-to-product bridge table arrived with an FAERS cluster in a demographic the trials under-enrolled for pharmacovigilance medical reviewer. That is a Pharma & Life Sciences CMC and Development Pathways decision on the primary endpoint will in a mid-size sponsor after a complete response letter.

DECISION Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after an FAERS cluster in a demographic the trials under-enrolled. 2. Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after an FAERS cluster in a demographic the trials under-enrolled for pharmacovigilance medical reviewer. 3. Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after an FAERS cluster in a demographic the trials under-enrolled. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision the primary endpoint will turns on in 505(b)(2) literature-to-product bridge table.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 2. Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim pharmacovigilance medical reviewer would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read 505(b)(2) literature-to-product bridge table against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move the primary endpoint will for pharmacovigilance medical reviewer.

RECOMMENDATION Do not close the primary endpoint will from a generic Pharma & Life Sciences playbook. 505(b)(2) literature-to-product bridge table after an FAERS cluster in a demographic the trials under-enrolled either supports Proceed under protocol for pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter, supports Pause the pathway, or is incomplete — in which case pharmacovigilance medical reviewer must state the unresolved clinical or safety evidence requirement explicitly.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in 505(b)(2) literature-to-product bridge table, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against 505(b)(2) literature-to-product bridge table: supported / rejected / untestable - Regulatory or exam hook CMC and Development Pathways would cite - CMC and Development Pathways finding in 505(b)(2) literature-to-product bridge table that a second reviewer can re-perform